MMP-2 Regulates Erk1/2 Phosphorylation and Aortic Dilatation in Marfan Syndrome

被引:97
|
作者
Xiong, Wanfen [1 ]
Meisinger, Trevor [1 ]
Knispel, Rebecca [1 ]
Worth, Jennifer M. [1 ]
Baxter, B. Timothy [1 ]
机构
[1] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE USA
基金
美国国家卫生研究院;
关键词
aortic aneurysms; doxycycline; losartan; Marfan syndrome; matrix metalloproteinases; transforming growth factor-beta; BETA-BLOCKER THERAPY; TGF-BETA; MOUSE MODEL; TUMOR INVASION; IN-VITRO; ANEURYSM; PATHOGENESIS; TETRACYCLINE; DOXYCYCLINE; ACTIVATION;
D O I
10.1161/CIRCRESAHA.112.268268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Aneurysm and dissection of the ascending thoracic aorta are the main cardiovascular complications of Marfan syndrome (MFS) resulting in premature death. Studies using mouse models of MFS have shown that activation of transforming growth factor-beta (TGF-beta) and the concomitant upregulation of matrix metalloproteinases (MMPs) contribute to aneurysm development. Our previous study showed that doxycycline delayed aneurysm rupture in a mouse model of MFS, Fbn1(mgR/mgR). Losartan has been shown to prevent aneurysms in another mouse model of MFS, Fbn1(C1039G/+), through inhibition of the Erk1/2 pathway. However, the role of MMP-2 in MFS and effect of losartan on the lifespan of MFS mice remain unknown. Objective: We investigated the role of MMP-2 in MFS and compared the effects of losartan and doxycycline on aortic dilatation and survival in Fbn1(mgR/mgR) mice. Methods and Results: By life table analysis, we found that losartan and doxycycline improved the survival of Fbn1(mgR/mgR) mice. Gelatin zymography and Western blot data showed that only doxycycline inhibited MMP-2 expression, whereas both drugs decreased Erk1/2 phosphorylation. When combined, only one of nine mice died within the 30-week study; aortic histology and diameter were normalized and the effects on Smad2 phosphorylation was additive. To further explore the role of MMP-2 in MFS, we created MMP-2-deficient Fbn1(mgR/mgR) mice. MMP-2 deletion inhibited activation of TGF-beta and phosphorylation of Erk1/2 and Smad2 and prolonged the lifespan of the mice. Conclusions: These studies demonstrated that inhibition of MMP-2 by doxycycline delayed the manifestations of MFS, in part, through its ability to decrease active TGF-beta and the noncanonical signaling cascade downstream of TGF-beta. This study further suggested that targeting TGF-beta signaling at different points might be a more effective strategy for inhibiting disease progression. (Circ Res. 2012; 110:e92-e101.)
引用
收藏
页码:E92 / E101
页数:10
相关论文
共 50 条
  • [41] The molecular mechanism by which ERK1/2 regulates CAR activation
    Osabe, Makoto
    DRUG METABOLISM REVIEWS, 2009, 41 : 169 - 169
  • [42] CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL
    Gilley, Rebecca
    Lochhead, Pamela A.
    Balmanno, Kathryn
    Oxley, David
    Clark, Jonathan
    Cook, Simon J.
    CELLULAR SIGNALLING, 2012, 24 (01) : 170 - 180
  • [43] ERK1/2 regulates epidermal chemokine expression and skin inflammation
    Pastore, S
    Mascia, F
    Mariotti, F
    Dattilo, C
    Mariani, V
    Girolomoni, G
    JOURNAL OF IMMUNOLOGY, 2005, 174 (08): : 5047 - 5056
  • [44] Warfarin Induces Calcification of the Aortic Valve via ERK1/2
    Venardos, Neil
    Weyant, Michael J.
    Reece, Thomas B.
    Meng, Xianzhong
    Fullerton, David A.
    CARDIOLOGY, 2016, 134 (02) : 208 - 208
  • [45] Effect of desipramine on ERK1/2 protein expression and differential role of alpha1-adrenergic receptor subtypes in modulation of the ERK1/2 phosphorylation
    Kusmierczyk, J.
    Chorazka, K.
    Smialek, J.
    Nalepa, I.
    FEBS OPEN BIO, 2019, 9 : 187 - 187
  • [46] Fragment-based discovery of a highly potent, orally bioavailable ERK1/2 inhibitor that modulates the phosphorylation and catalytic activity of ERK1/2
    Heightman, Tom D.
    Berdini, Valerio
    Braithwaite, Hannah
    Buck, Ildiko
    Cassidy, Megan
    Castro, Juan
    Courtin, Aurelie
    Day, James
    East, Charlotte
    Fazal, Lynsey
    Graham, Brent
    Griffiths-Jones, Charlotte
    Lyons, John
    Martins, Vanessa
    Muench, Sandra
    Munck, Joanne
    Norton, David
    O'Reilly, Marc
    Palmer, Nick
    Pathuri, Puja
    Reader, Mike
    Rees, David
    Rich, Sharna
    Richardson, Caroline
    Saini, Harpreet
    Thompson, Neil
    Wallis, Nicola
    Walton, Hugh
    Wilsher, Nicola
    Woolford, Alison
    Murray, Chris
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [47] Rubus idaeus extract suppresses migration and invasion of human oral cancer by inhibiting MMP-2 through modulation of the Erk1/2 signaling pathway
    Huang, Yi-Wen
    Chuang, Chun-Yi
    Hsieh, Yih-Shou
    Chen, Pei-Ni
    Yang, Shun-Fa
    Shih-Hsuan-Lin
    Chen, Yang-Yu
    Lin, Chiao-Wen
    Chang, Yu-Chao
    ENVIRONMENTAL TOXICOLOGY, 2017, 32 (03) : 1037 - 1046
  • [48] Iron regulates MT1-MMP-mediated MMP-2 activation in cancer cells
    Takino, Takahisa
    Takatsuka, Risa
    Suzuki, Takeshi
    CANCER SCIENCE, 2025, 116 : 1611 - 1611
  • [49] Iron regulates MT1-MMP-mediated MMP-2 activation and cell invasion
    Takino, Takahisa
    Takatsuka, Risa
    Suzuki, Takeshi
    CANCER SCIENCE, 2024, 115 : 1342 - 1342
  • [50] Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation
    Sariahmetoglu, Meltem
    Crawford, Bryan D.
    Leon, Hernando
    Sawicka, Jolanta
    Li, Laiji
    Ballermann, Barbara J.
    Holmes, Charles
    Berthiaume, Luc G.
    Holt, Andrew
    Sawicki, Grzegorz
    Schulz, Richard
    FASEB JOURNAL, 2007, 21 (10): : 2486 - 2495